mirosamicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

mirosamicin: a mycinamicin; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	49787022
CHEBI ID	80018
MeSH ID	M0174171

Synonyms (5)

Synonym
mycinamicin ii
73684-69-2
mirosamicin
CHEBI:80018
Q27149164

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" Therefore, its LD50 values were estimated to be greater than 2,500 mg/kg for mice and greater than 2,000 mg/kg for rats."	( [Acute toxicity studies of miporamicin and its degradation products and metabolites in the mouse and rat]. Matsumoto, K; Motoyama, K; Sano, K; Sasaki, M; Sumi, A; Yamamoto, H; Yano, J, 1989)	0.28
" Histopathologic examination revealed no adverse toxicologic changes other than spontaneous or aging-associated ones."	( [Six-month chronic toxicity study of miporamicin in rats]. Matsumoto, K; Miura, M; Morino, T; Motoyama, K; Sumi, A; Yamamoto, H; Yano, J, 1989)	0.28

Dosage Studied

Excerpt	Relevance	Reference
" Following oral administration of miporamicin (MPM), none died among mice or rats even at the highest dosage levels."	( [Acute toxicity studies of miporamicin and its degradation products and metabolites in the mouse and rat]. Matsumoto, K; Motoyama, K; Sano, K; Sasaki, M; Sumi, A; Yamamoto, H; Yano, J, 1989)	0.28
"A 28-day oral dosage test of miporamicin (MPM), a new macrolide antibiotic, was performed to assess its toxicologic potential in groups of male and female rats receiving the compound in feed."	( [Subacute toxicity study of miporamicin in rats by twenty-eight-day administration in feed]. Matsumoto, K; Miura, M; Morino, T; Motoyama, K; Sumi, A; Yamamoto, H; Yano, J, 1989)	0.28
" No death occurred at any dosage levels throughout the study period."	( [Six-month chronic toxicity study of miporamicin in rats]. Matsumoto, K; Miura, M; Morino, T; Motoyama, K; Sumi, A; Yamamoto, H; Yano, J, 1989)	0.28
" The drug was mixed with pollen-substitute paste and administered to honeybee colonies continuously for a week at a dosage of 200 mg/hive/week."	( Disposition of mirosamicin in honeybee hives. Hayama, T; Nakajima, C; Nakamura, A; Okayama, A; Sakogawa, T, 1998)	0.3

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
macrolide	A macrocyclic lactone with a ring of twelve or more members derived from a polyketide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (12)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	8 (66.67)	18.7374
1990's	3 (25.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (8.33)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (8.33%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (91.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
glutaral Glutaral: One of the protein CROSS-LINKING REAGENTS that is used as a disinfectant for sterilization of heat-sensitive equipment and as a laboratory reagent, especially as a fixative.. glutaraldehyde : A dialdehyde comprised of pentane with aldehyde functions at C-1 and C-5.	3.09	1	0	dialdehyde	cross-linking reagent; disinfectant; fixative

Condition	Relationship Strength	Studies
Acute Hypercapnic Respiratory Failure [description not available]	1.97	1
Respiratory Insufficiency Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)	1.97	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.89	4
Fetal Death Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.	1.97	1
Abnormalities, Drug-Induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.	2.38	2
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.38	2
Anaphylactic Reaction [description not available]	1.97	1
Contact Dermatitis [description not available]	1.97	1
Anaphylaxis An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.	1.97	1
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	1.97	1
Abnormalities, Autosome [description not available]	1.97	1

chemdatabank.com